All Stories

  1. The burden of hypercholesterolemia and ischemic heart disease in an ageing world
  2. Lipid-lowering treatment and LDL-C goal attainment in high and very high cardiovascular risk patients: Evidence from the SANTORINI study-The Italian experience
  3. Remnant cholesterol: a reliable prognostic marker?
  4. Lp(a) as a Cardiovascular Risk Factor
  5. Inclisiran: How Widely and When Should We Use It?
  6. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
  7. Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
  8. Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia
  9. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
  10. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
  11. Lipoprotein remnants: to be or not to be
  12. Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?
  13. HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases
  14. Global epidemiology of dyslipidaemias
  15. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors
  16. The cardiovascular benefit of Lp(a) reduction: not there yet
  17. LDL-Cholesterol-Lowering Therapy
  18. Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects
  19. Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation
  20. Cholesterol metabolism, pancreatic β-cell function and diabetes
  21. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion
  22. Statins increase Lp(a) plasma level: is this clinically relevant?
  23. Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation
  24. Biological Consequences of Dysfunctional HDL
  25. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
  26. Novel strategies to target PCSK9: beyond monoclonal antibodies
  27. Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?
  28. Lipid Lowering and Incidence of Cataract, a Role for Fibrates
  29. High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?
  30. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
  31. PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
  32. Proprotein Convertase Subtilisin Kexin 9 Inhibitors
  33. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
  34. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey
  35. Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
  36. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study
  37. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
  38. Strategies for the use of nonstatin therapies
  39. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies
  40. Effect of PSCK9 loss-of-function mutation R46l on plasma lipids, endothelial function and vascular inflammation in the post-prandial state
  41. PCSK9 inhibition in statin-intolerant HeFH patients: What’s new?
  42. Pitavastatin and HDL: Effects on plasma levels and function(s)
  43. Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
  44. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
  45. Familial Hypercholesterolemia
  46. Advances in Hypercholesterolemia
  47. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
  48. Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
  49. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies
  50. Apolipoprotein C-III: From Pathophysiology to Pharmacology
  51. Statin Intolerance: Diagnosis and Remedies
  52. Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
  53. Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?
  54. HDL in Infectious Diseases and Sepsis
  55. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus
  56. HDL in innate and adaptive immunity
  57. HDL: To Treat or Not To Treat?
  58. Postprandial lipemia as a cardiometabolic risk factor
  59. 15-Lipoxygenase-Mediated Modification of HDL3 Impairs eNOS Activation in Human Endothelial Cells
  60. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia
  61. Prevalence of classical CD14++/CD16− but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia
  62. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia
  63. Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States
  64. Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
  65. LOX-1, OxLDL, and Atherosclerosis
  66. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
  67. Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases
  68. Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins
  69. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
  70. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models
  71. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models
  72. Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population
  73. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
  74. Emerging role of high density lipoproteins as a player in the immune system
  75. HDLs, immunity, and atherosclerosis
  76. Therapy and clinical trials
  77. Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro
  78. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells
  79. Dual effect of hypochlorite in the modification of high density lipoproteins
  80. The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders
  81. The 15-lipoxygenase-modified HDL3 fail to inhibit the TNF- -induced inflammatory response in human endothelial cells
  82. The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- -Induced Inflammatory Response in Human Endothelial Cells
  83. EFFECTS OF NATIVE AND MODIFIED HDL ON HUMAN IMMUNE FUNCTIONS
  84. Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells
  85. Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux
  86. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice
  87. Modified HDL: Biological and physiopathological consequences
  88. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages
  89. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels
  90. Th-P15:162 15-Lipoxygenase-mediated modification of high density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages
  91. Proteome of endothelial cell-derived procoagulant microparticles
  92. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization
  93. Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-κB, CRE dependent pathway and affect PGE2 synthesis
  94. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL
  95. Statins and Oxidative Stress During Atherogenesis
  96. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini
  97. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini
  98. Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs
  99. Modification of high density lipoproteins: Effects on OxLDL cytotoxicity and on cholesterol efflux
  100. Enhanced Macrophage Uptake of Elastase-Modified High-Density Lipoproteins
  101. Oxidized Lipoproteins and Endothelium
  102. Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells
  103. Procyanidines from vitis vinifera seeds protect low density lipoproteins from oxidation
  104. Endothelium and oxidised lipoproteins
  105. Chronic stimulation by insulin induces HSP60 expression in cultured eahy cells
  106. Overexpression of HSP72 in COS-1 cells does not protect from apoptosis induced by oxidized LDL
  107. 3.P.87 Two distinct components of oxidized LDL mediate the heat shock response and cytotoxicity triggered by OxLDL
  108. 3.P.255 Cholesterol biosynthesis pathway is involved in the heat shock protein and cytotoxic indicated by oxidized LDL in cultured human endothelial cells and smooth muscle cells
  109. Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells
  110. Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating
  111. Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells
  112. Oxidized LDL induce hsp70 expression in human smooth muscle cells
  113. Oxidized lipoproteins induce long-lasting inhibition of nitric oxide synthase from a murine endothelioma cell line (bEnd.4)
  114. Oxidized Lipoproteins Induce Long-Lasting Inhibition of Nitric Oxide Synthase from a Murine Endothelioma Cell Line (bEnd.4)
  115. Constituents of Nothapodytes foetida